ImmunityBio (United States)

Recent papers from ImmunityBio (United States)

1. Env-specific antibodies promote post-treatment control in SIV-infected macaquesNature Microbiology · 2026
2. Viral Genetic Traits of Durable Control in Dual Immunotherapy-treated SHIV-infected Rhesus MacaquesVirus Evolution · 2026
3. Epigenetic plus cytokine therapy induces stem-like CD8 + T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistanceJournal for ImmunoTherapy of Cancer · 2026
4. Improved natural killer cell targeting of prostate carcinoma with ATR inhibitor tuvusertib in combination with IL-15 receptor superagonist N-803 2299576The Journal of Immunology · 2026
5. Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary DiseaseThe Journal of Urology · 2026
6. Pre-treatment Gut Microbiome Diversity and Function Linked to Cytotoxic and Natural Killer Cell Immune Responses after N-803 Treatment in People with HIVClinical Infectious Diseases · 2026
7. Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancerJournal for ImmunoTherapy of Cancer · 2026
8. Elevated CO ₂ and Water Limitation Alter the Primary Metabolite Composition of Mealybug Honeydew, Reducing Parasitoid FitnessJournal of Agricultural and Food Chemistry · 2026
9. A matched-adjusted indirect comparison (MAIC) of nogapendekin alfa inbakicept-pmln plus bacillus Calmette–Guérin (NAI+BCG) and pembrolizumab in patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ± papillary disease.Journal of Clinical Oncology · 2026
10. Response in first-in-human chemotherapy-free combination immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): Nogapendekin alfa inbakicept (NAI) and PD-L1 t-haNK plus bevacizumab (BEV).Journal of Clinical Oncology · 2026
11. Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy.Journal of Clinical Oncology · 2026
12. Efficacy outcomes in first-line (1L) non–small cell lung cancer (NSCLC) with maintenance of immune competence: QUILT-2.023 randomized phase 3 study of IL-15R agonist nogapendekin alfa inbakicept (NAI) with checkpoint inhibitor (CPI) ± chemotherapy.Journal of Clinical Oncology · 2026
13. D107-03 Novel Interleukin-15 Superagonist (n-803) and Invariant Natural Killer T Cell (agent-797) Combination Immunotherapy for Unresolving Coccidioides Immitis InfectionAmerican Journal of Respiratory and Critical Care Medicine · 2026
14. Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)Frontiers in Immunology · 2026
15. Rapid suppression of unresolving disseminated coccidioidomycosis infection with combined IL-15 super-agonist (N-803) and invariant natural killer T cell therapyClinical Immunology Communications · 2026
16. Abstract 447: A M2-like tumor-associated macrophage-targeted nanoparticulate TLR7/8 agonist, UI-102, reprograms its phenotypes to induce potent anti-tumor immunity.Cancer Research · 2026
17. 151TiP Phase III trial ResQ201A of NAI plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapyESMO Open · 2026
18. ResQ133A-NMIBC: A phase 1/2 clinical trial of intravesical recombinant mycobacterium bacillus Calmette-Guerin (rBCG) in participants living with non-muscle invasive bladder cancer eligible to receive conventional BCG.Journal of Clinical Oncology · 2026
19. Abstract A027: Peripheral Immune Dynamics and Biomarkers of Clinical Response in Patients with Castration-Resistant Prostate Cancer Treated with Combination ImmunotherapyCancer Immunology Research · 2026
20. Abstract A018: Characterization of the anti-tumor efficacy of memory cytokine enriched NK cells against tumors with neuroendocrine featuresCancer Immunology Research · 2026